How Lymphoma Treatment Is Planned: Hodgkin Versus Non-Hodgkin and What Subtype Changes

The oncologist slides the pathology report across the desk and circles one line. Not the word lymphoma, which the patient has already spent three sleepless nights reading about, but a name underneath it that she has never seen: nodular sclerosis classical Hodgkin lymphoma. “This,” the doctor says, “is what we plan around.”

That moment repeats itself in clinics everywhere. People arrive braced for the diagnosis and discover that the real conversation is about the fine print. In the world of hodgkin vs non hodgkin lymphoma treatment, the distinction between the two families matters, but the subtype inside each family, the stage, and the person’s own health matter at least as much.

This explainer walks through how a lymphoma treatment plan is actually built, why two people with “lymphoma” can leave the same clinic with completely different calendars, and which questions are worth asking before the first appointment ends.

What is the difference between Hodgkin and non-Hodgkin lymphoma?

Lymphoma is a cancer of lymphocytes, the white blood cells that patrol the lymph nodes, spleen, bone marrow and the lymphatic vessels that connect them. The difference between Hodgkin and non-Hodgkin lymphoma comes down to what a pathologist sees when a node is examined under the microscope.

Hodgkin lymphoma is defined by the presence of Reed-Sternberg cells, which are unusually large, abnormal B lymphocytes, often with two nuclei that give them a distinctive appearance. Find those cells, surrounded by a crowd of reactive immune cells, and the diagnosis is Hodgkin lymphoma. Everything else is grouped, somewhat unhelpfully, as non-Hodgkin lymphoma.

That single negative word covers enormous variety. The National Cancer Institute describes non-Hodgkin lymphoma as many different diseases rather than one, arising from B cells, T cells or natural killer cells, and behaving anywhere from very slowly to very aggressively. Hodgkin lymphoma, by contrast, is a smaller and more uniform group. MedlinePlus notes that it most often appears in younger adults and in people over 55, and that it typically spreads in an orderly way from one group of lymph nodes to the next.

Why does a nineteenth-century pathologist’s name still shape treatment? Because the two families respond differently to different drugs, spread differently, and are staged with slightly different emphasis. A plan that suits classical Hodgkin lymphoma would be wrong for a slow-growing follicular lymphoma, and vice versa. The label is the first branch in a decision tree, and the biopsy is what tells the team which branch to take.

Two things are true at once. The Hodgkin and non-Hodgkin split is real and clinically useful. It is also only the beginning of the answer.

How Hodgkin vs non-Hodgkin lymphoma treatment planning actually works

Treatment planning follows a sequence that looks similar across both families, even when the resulting plans diverge. It begins with tissue, moves to imaging and blood work, and ends with a multidisciplinary discussion.

The first step is a biopsy, ideally an excisional biopsy in which a whole lymph node is removed, or a core biopsy that takes a substantial sample. Fine-needle aspiration alone is usually not enough, because the pathologist needs to see the architecture of the node, not just loose cells. The Mayo Clinic describes this tissue examination, including immunophenotyping, as the foundation of the diagnosis. Immunophenotyping is a laboratory test that identifies which proteins sit on the surface of the cancer cells, such as CD20 or CD30, and those proteins later become targets for treatment.

Next comes staging. A PET-CT scan, which combines a metabolic scan showing where cells are burning sugar rapidly with an anatomical CT, has become the standard way to map lymphoma in the body. Blood tests check liver and kidney function, blood counts and, for some subtypes, a marker called LDH that rises when cells turn over quickly. A bone marrow biopsy is sometimes needed, particularly in non-Hodgkin lymphoma, although PET-CT has reduced how often it is required in Hodgkin lymphoma.

Then the case goes to a tumor board or multidisciplinary meeting, where hematologists, oncologists, radiologists, pathologists and radiation specialists agree on a plan. Only after that does a patient hear a recommendation.

Fitness for treatment is weighed alongside the disease itself. Heart function, lung function, age, other illnesses and the person’s own priorities all shape what is offered. Two people with identical scans can reasonably receive different plans, and that is not inconsistency. It is medicine adjusting to the person in front of it.

Why the biopsy report matters more than the word lymphoma

If one point deserves emphasis above all others, it is this: the subtype on the pathology report drives treatment more than the Hodgkin or non-Hodgkin heading does.

Within Hodgkin lymphoma there are two main groups. Classical Hodgkin lymphoma, which the NCI describes as accounting for the large majority of cases, has four further subtypes: nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-depleted. These are usually treated in similar ways. The second group, nodular lymphocyte-predominant Hodgkin lymphoma, behaves more like a slow-growing B-cell lymphoma, lacks the classic Reed-Sternberg pattern, and is often approached differently.

Within non-Hodgkin lymphoma the range is far wider. Diffuse large B-cell lymphoma is the most common aggressive subtype and typically needs prompt treatment. Follicular lymphoma is the most common slow-growing subtype and may not need treatment straight away. Mantle cell lymphoma, marginal zone lymphoma, Burkitt lymphoma and the various T-cell lymphomas each have their own natural history and their own standard approaches. The NHS notes that non-Hodgkin lymphomas are broadly divided into high-grade, meaning fast-growing, and low-grade, meaning slow-growing, and that this grade shapes treatment decisions.

Modern pathology adds further layers. Genetic tests can identify rearrangements in genes such as MYC or BCL2 that mark a more aggressive course. Cell-of-origin testing distinguishes germinal center from activated B-cell types. None of these appear in the headline word on the report, yet they can change the intensity of treatment that is offered.

A practical consequence follows. Patients who ask “What subtype is it?” and “What did the immunophenotyping show?” learn more about their likely path than those who ask only whether it is Hodgkin or not. The subtype is the sentence worth writing down.

Lymphoma treatment by stage: what the Roman numerals mean

Staging describes how far a lymphoma has spread, and both families use the same basic framework, historically called the Ann Arbor system and updated as the Lugano classification. The NCI patient summaries for both Hodgkin and non-Hodgkin lymphoma lay out four stages.

Stage I means one lymph node region, or a single organ outside the nodes, is involved. Stage II means two or more node regions on the same side of the diaphragm, the sheet of muscle that separates chest from abdomen. Stage III means nodes on both sides of the diaphragm are affected. Stage IV means the lymphoma has spread widely into organs such as the bone marrow, liver or lungs.

Letters are added for context. The letter B signals what doctors call B symptoms: unexplained fever, drenching night sweats, or significant unintended weight loss. Their absence earns an A. The letter E marks disease extending into tissue next to a node, and the term bulky refers to a large mass, defined by size on the scan, which may prompt additional treatment such as radiotherapy.

Here is where Hodgkin and non-Hodgkin lymphoma treatment begin to part ways. In classical Hodgkin lymphoma, stage sorts patients into early-stage and advanced-stage groups that receive different numbers of chemotherapy cycles and different decisions about radiotherapy. In aggressive non-Hodgkin lymphoma, stage still matters, but a prognostic score that also weighs age, LDH level, performance status and the number of sites outside the nodes often influences intensity. In slow-growing non-Hodgkin lymphoma, stage matters less than symptoms, because many people are diagnosed at stage III or IV and still do not need immediate treatment.

Stage IV sounds frightening. In lymphoma it does not carry the same meaning it does in many solid tumors, because lymphocytes naturally travel throughout the body, and the disease remains treatable at every stage. The number tells the team how much territory to cover, not whether to try.

Is Hodgkin lymphoma treatable? How the plan is usually built

Hodgkin lymphoma is widely regarded as one of the more treatable cancers, and the NHS describes it as a condition where most people can expect treatment to be effective, with the aim being to bring the disease fully under control. The precise numbers belong in a conversation with the treating team, who can relate them to an individual’s stage and health rather than to a population average.

The standard approach for classical Hodgkin lymphoma is combination chemotherapy, meaning several drugs with different mechanisms given together so that cancer cells cannot easily escape all of them. The regimens used have been refined over decades and are given in cycles, with rest periods to let normal blood cells recover. For early-stage disease, a shorter course of chemotherapy may be followed by radiotherapy to the involved nodes. For advanced disease, more cycles are typically given, and radiotherapy is reserved for specific situations such as bulky disease.

What has changed most in recent years is the use of PET-adapted treatment. After the first two cycles, a repeat PET-CT shows whether the lymphoma is responding. A negative scan can allow the team to reduce the intensity of what follows, sparing some of the long-term side effects on the heart and lungs. A positive scan can prompt escalation. This is a genuine example of treatment being planned around evidence gathered from the patient’s own body rather than from a textbook.

An antibody-drug conjugate targeting CD30, the protein found on Reed-Sternberg cells, has also entered front-line and relapse settings. It works by delivering a chemotherapy payload directly to cells carrying the target. Whether and where it fits in an individual plan is a decision for the treating team based on current guidance.

Nodular lymphocyte-predominant Hodgkin lymphoma sits apart. Because it behaves more like an indolent B-cell lymphoma, radiotherapy alone or anti-CD20 antibody therapy may be considered for limited disease.

Non-Hodgkin lymphoma treatment options for aggressive subtypes

Aggressive, or high-grade, non-Hodgkin lymphomas grow fast and usually need treatment to start within days to a few weeks of diagnosis. Diffuse large B-cell lymphoma is the archetype, and its standard first-line plan illustrates how the non-Hodgkin approach differs from Hodgkin.

The backbone is chemo-immunotherapy: a combination chemotherapy regimen paired with a monoclonal antibody. A monoclonal antibody is a laboratory-made protein designed to lock onto one specific target, in this case CD20, a marker found on most B-cell lymphomas but absent from Reed-Sternberg cells. Once attached, it flags the cell for destruction by the immune system and can trigger cell death directly. The Mayo Clinic lists these antibodies alongside chemotherapy as core options for non-Hodgkin lymphoma. Because Hodgkin lymphoma cells generally do not carry CD20, this is one concrete reason the two diseases are treated differently.

Cycles are given at set intervals, typically every few weeks according to the NHS, for a number of cycles determined by stage and response. Limited-stage disease may receive fewer cycles, sometimes with radiotherapy to the affected area. Some patients receive preventive treatment directed at the central nervous system if their subtype or disease location carries a higher risk of spread there.

Other aggressive subtypes have their own standards. Burkitt lymphoma is treated with intensive, short-interval regimens because it doubles in size so quickly. Mantle cell lymphoma often incorporates targeted oral drugs. Peripheral T-cell lymphomas use different combinations because they lack CD20 altogether. Each of these is a distinct plan, not a variation on a single theme.

Relapsed or refractory aggressive lymphoma has its own pathway, which may include high-dose chemotherapy with stem cell rescue, CAR T-cell therapy, or bispecific antibodies. These are discussed later, but the principle is the same throughout: the subtype and the surface markers on the cells decide the tools.

Who is usually asked to wait: indolent lymphoma and active monitoring

Few conversations in oncology surprise patients more than being told they have cancer and that the plan, for now, is to do nothing. Yet for many people with slow-growing non-Hodgkin lymphoma, active monitoring is the evidence-based recommendation.

Indolent lymphomas such as follicular lymphoma, marginal zone lymphoma and small lymphocytic lymphoma often cause no symptoms for years. Treating them early, before they cause problems, has not been shown to help people live longer or feel better, while it does expose them to side effects. The NHS describes this approach for low-grade non-Hodgkin lymphoma as watch and wait, with regular check-ups and treatment started only when needed.

What triggers treatment? Doctors look for symptoms such as B symptoms or discomfort from enlarged nodes, for nodes growing quickly or reaching a size that threatens an organ, for falling blood counts caused by marrow involvement, and for signs that the lymphoma may be transforming into a more aggressive type. Any of these can shift the plan from monitoring to treatment.

When treatment does start, the options for indolent lymphoma often differ from those for aggressive disease. A single anti-CD20 antibody without chemotherapy may be appropriate for some. Others receive chemo-immunotherapy, sometimes followed by maintenance antibody therapy over a longer period. Radiotherapy alone can be enough for early-stage disease confined to one area. Targeted oral drugs are increasingly used at relapse.

Who is not asked to wait? Anyone with aggressive lymphoma, anyone whose indolent lymphoma is causing symptoms or organ compression, and almost everyone with classical Hodgkin lymphoma, which is treated soon after diagnosis regardless of stage.

Living with monitored lymphoma carries its own psychological weight. Naming that burden, and asking the team what support is available, is a legitimate part of the treatment plan.

Hodgkin vs non-Hodgkin lymphoma treatment at a glance

The table below draws together the main differences in how the two families are approached. It summarizes typical patterns described in the NCI and NHS resources; individual plans vary, and the treating team’s recommendation always takes precedence.

Feature	Classical Hodgkin lymphoma	Non-Hodgkin lymphoma
Defining cell	Reed-Sternberg cells present	Reed-Sternberg cells absent; many cell types
Number of subtypes	Few, mostly treated similarly	Dozens, treated very differently
Usual pace	Treatment begins soon after diagnosis	Ranges from urgent to years of monitoring
Main first-line approach	Combination chemotherapy, often PET-adapted	Depends on grade; chemo-immunotherapy common for aggressive B-cell types
Key surface target	CD30	CD20 on most B-cell types; varies for T-cell
Role of radiotherapy	Common in early stage and for bulky disease	Selected cases, especially limited-stage
Active monitoring	Rare	Standard for many indolent subtypes
Mid-treatment PET scan	Routinely guides intensity	Used for response; less often changes plan

Two rows deserve a second look. The surface-target row explains, in a single line, why an antibody that works well in one family has little role in the other. The active-monitoring row explains why a person with stage IV follicular lymphoma may be scheduled for a scan in six months, while a person with stage II Hodgkin lymphoma starts chemotherapy the following week.

Neither column is universally easier. The Hodgkin column is more predictable. The non-Hodgkin column contains both the most urgent and the most leisurely plans in all of lymphoma care, which is exactly why the subtype has to be known before anything else is decided.

Where targeted drugs, immunotherapy, CAR T cells and transplants fit

Newer treatments generate headlines, and patients understandably ask whether they should be receiving them. The honest answer is that most sit in specific slots within the plan, defined by subtype, prior treatment and current guidance, rather than being better versions of first-line therapy for everyone.

Targeted therapy refers to drugs that interfere with a particular molecular pathway the lymphoma cells rely on. Examples include inhibitors of enzymes inside B cells that drive survival signals. These are used in several non-Hodgkin subtypes, particularly at relapse or for mantle cell and chronic lymphocytic types, and typically not in classical Hodgkin lymphoma.

Immunotherapy is a broader term for treatments that help the immune system attack the cancer. Checkpoint inhibitors, which release a brake on T cells, have a recognized role in relapsed classical Hodgkin lymphoma, because Reed-Sternberg cells are unusually rich in the proteins those brakes rely on. Bispecific antibodies, which bind a cancer cell with one arm and a T cell with the other, are entering practice for some relapsed B-cell non-Hodgkin lymphomas.

CAR T-cell therapy takes a patient’s own T cells, re-engineers them in a laboratory to recognize a protein such as CD19 on lymphoma cells, and returns them by infusion. The NCI describes it as an option for certain relapsed or refractory non-Hodgkin lymphomas. It requires specialized centers and carries distinctive short-term risks, including a systemic inflammatory reaction and temporary neurological effects, which the treating team will explain in detail.

Stem cell transplant, in the form most used for lymphoma, involves collecting a person’s own blood-forming cells, giving very high-dose chemotherapy, then returning the cells to rebuild the marrow. It is mainly considered for relapsed disease in both families.

Each of these belongs to a decision that weighs benefit, risk and alternatives for one person. Asking whether they apply is reasonable. Expecting them as a default is not how the evidence currently points.

What the following weeks usually look like once treatment begins

The first cycle sets the pattern. Most lymphoma chemotherapy is given as an outpatient infusion, so people go home the same day, with a line placed in a vein or, for longer courses, a semi-permanent central line to spare the arm veins. The NHS describes courses lasting several months, delivered in cycles with rest periods in between.

The days after an infusion often bring fatigue, and for some, nausea that is now usually well controlled with preventive medicines chosen by the team. Hair thinning, when it occurs, typically begins after the first few weeks. Blood counts fall to their lowest point roughly a week to two weeks into each cycle, which is when infection risk is highest and when the team will want to hear about any fever promptly. Counts then recover before the next cycle, and that recovery is checked with a blood test beforehand.

Somewhere around the second or third cycle, a repeat PET-CT is common. In Hodgkin lymphoma this scan may change the rest of the plan. In aggressive non-Hodgkin lymphoma it confirms the disease is responding. An end-of-treatment scan follows the final cycle to assess the overall response.

Radiotherapy, when it is part of the plan, usually comes after chemotherapy and is delivered in short daily sessions over a few weeks, targeted to the areas that were involved. Its side effects depend on the region treated: a sore throat or dry mouth for neck fields, tiredness almost everywhere.

Follow-up after treatment stretches over years, with visits spaced further apart as time passes. The Mayo Clinic notes that late effects, including heart and lung changes and second cancers, are monitored particularly after chest radiotherapy or certain chemotherapy drugs, which is one reason modern plans try to minimize both where the evidence allows.

Every timeline above is a typical pattern, not a schedule anyone can promise. The team adjusts as the body responds.

Which is easier to treat, Hodgkin or non-Hodgkin lymphoma? An honest answer

This is the question people type most often, and the fair answer is that it is the wrong comparison. Hodgkin lymphoma, as a group, is highly responsive to standard treatment, and the NHS and NCI both describe it as among the more treatable cancers. But comparing it with non-Hodgkin lymphoma is like comparing one species with an entire kingdom.

Some non-Hodgkin subtypes respond to first-line treatment as reliably as Hodgkin lymphoma does. Diffuse large B-cell lymphoma, for instance, is an aggressive disease that is nonetheless often brought fully under control with chemo-immunotherapy. Other subtypes, including some T-cell lymphomas and some relapsed disease, remain genuinely difficult. Indolent subtypes occupy a third category: they are rarely eliminated outright, yet many people live with them for decades, treated intermittently when the disease becomes active.

That third category answers another common question, whether non-Hodgkin lymphoma ever goes away. For aggressive subtypes, the goal of treatment is complete remission, meaning no detectable disease on scans and tests, with the hope that it does not return. For indolent subtypes, the realistic framing is long-term control, with periods of remission and, for many, long stretches needing no treatment at all. Both are meaningful outcomes, and both are different from what the word cancer conjures for most people.

Is non-Hodgkin lymphoma serious? Yes, in the sense that every cancer is. It is also one of the cancers where treatment has changed the outlook most dramatically over recent decades, largely because of monoclonal antibodies and better supportive care.

What matters most, then, is not which family a person falls into but which subtype, which stage, how the disease responds to the first cycles, and how fit the person is to receive treatment. Those four factors carry far more weight than the historical dividing line.

What people often get wrong about lymphoma treatment

Certain misunderstandings surface again and again in clinic, and correcting them early spares people unnecessary fear or misplaced reassurance.

The first is that stage IV means the end. In lymphoma, stage IV describes distribution, and lymphocytes are designed to travel. Advanced-stage Hodgkin lymphoma and advanced-stage aggressive non-Hodgkin lymphoma are both treated with the intention of complete remission, and advanced-stage indolent lymphoma is frequently monitored rather than treated at all.

The second is the mirror image: that watch and wait means the doctors have given up. It means the opposite. The evidence shows that people with symptom-free indolent lymphoma do no better with early treatment, so the team is protecting them from side effects until treatment has something to offer.

The third is that Hodgkin is the good lymphoma and non-Hodgkin the bad one. As the previous section explained, non-Hodgkin lymphoma contains subtypes that respond as well as Hodgkin lymphoma and subtypes that do not. The label alone predicts little.

The fourth is that newer must mean better. CAR T cells, bispecific antibodies and targeted drugs are remarkable, but most have their best evidence in relapsed disease, and first-line chemo-immunotherapy remains the standard for many subtypes because it works for a large proportion of people with a known safety profile.

The fifth is that supplements or special diets can treat lymphoma. The NIH Office of Dietary Supplements is clear that no supplement has been shown to treat cancer, and some, including high-dose antioxidants and certain herbal products, can interfere with chemotherapy or affect liver function. Eating well and staying active support recovery; they are not treatment, and anything being taken should be disclosed to the team.

The sixth is that a family history of lymphoma means children will inherit it. Most lymphoma is not hereditary, and the Mayo Clinic lists immune suppression and certain infections among the recognized risk factors rather than family patterns.

Questions to ask your care team

A first oncology appointment is a poor environment for memory. Writing questions down beforehand, and bringing someone to take notes, changes what people take home from it. These are the questions that most often unlock a clearer picture of the plan.

• What is the exact subtype, and what did the immunophenotyping and any genetic tests show?
• What is the stage, are there B symptoms or bulky disease, and how do those affect the plan you are recommending?
• Is this a lymphoma that needs treatment now, or one where monitoring is a reasonable option, and what would prompt a change?
• What is the goal of this treatment: complete remission, long-term control, or relief of symptoms?
• How many cycles are planned, how far apart, and will a scan partway through change the plan?
• Is radiotherapy likely to be part of the plan, and what are the trade-offs of including or omitting it?
• Which side effects should I expect in the first weeks, and which are the ones that mean I should call immediately?
• Are there long-term effects on the heart, lungs, fertility or future cancer risk that we should plan for now?
• Is fertility preservation something to discuss before the first cycle?
• Are there clinical trials appropriate for my subtype and stage?
• Who do I contact out of hours, and what number should I call for a fever?

Fertility deserves a particular mention because it is time-sensitive. Some regimens carry a risk to future fertility, and options such as sperm banking or egg or embryo freezing must be arranged before chemotherapy starts. Teams routinely raise this, but asking ensures it is not missed in the rush to begin.

Asking for a written summary of the plan, or a copy of the letter sent to the primary care doctor, is also reasonable and widely provided. The plan may change as scans come in, and having the original in hand makes those changes easier to follow.

When to call your doctor

Lymphoma treatment lowers the body’s defenses at predictable points, and the team will give specific instructions for the regimen being used. The following signs should always prompt a same-day call to the number provided, or emergency care if the team cannot be reached.

A fever, defined by the treating team’s threshold, is the most important. During chemotherapy, fever can be the only sign of a serious infection when white cell counts are low, and the NHS and Mayo Clinic both advise treating it as urgent rather than waiting to see whether it settles. Shaking chills, feeling suddenly very unwell, confusion or a rapid heartbeat alongside fever need emergency assessment.

Breathing difficulty, chest pain, or swelling of the face, neck or arms can indicate a large mass pressing on vessels or airways in the chest, a clot, or a reaction to treatment, and should not wait until morning. Unusual bleeding or bruising, blood in urine or stool, or a rash of tiny red spots may signal a low platelet count. Persistent vomiting that prevents fluids or medicines being kept down, severe diarrhea, or signs of dehydration such as dizziness on standing all warrant a call.

New numbness, weakness, severe headache, changes in vision or a seizure are urgent at any point in treatment, and particularly after CAR T-cell therapy or with subtypes known to involve the nervous system.

Between treatments and after it ends, new or enlarging lumps, a return of night sweats, unexplained weight loss, or fatigue that is clearly worsening rather than slowly lifting deserve a prompt appointment rather than waiting for the next scheduled scan.

None of this is intended as a checklist for self-diagnosis. Its purpose is the opposite: to lower the threshold for picking up the phone. Oncology teams would rather hear about a symptom that turns out to be nothing than learn about one too late. Every decision about what happens next rests with them.

Frequently asked questions

Which is easier to treat, Hodgkin's or non-Hodgkin's lymphoma?

Hodgkin lymphoma responds reliably to standard chemotherapy and is described by the NHS and NCI as among the more treatable cancers, but non-Hodgkin lymphoma is too varied for a single comparison. Some non-Hodgkin subtypes respond just as well; others are harder. The subtype, stage and the person’s fitness predict the course far better than which family the lymphoma belongs to.

Which lymphoma type is most treatable?

Classical Hodgkin lymphoma and several B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, are among the types most often brought into complete remission with first-line treatment. Slow-growing types such as follicular lymphoma are rarely eliminated but are often controlled for many years. Your treating team can explain what the evidence shows for your exact subtype and stage.

Do you ever get rid of non-Hodgkin's lymphoma?

For aggressive subtypes, the goal is complete remission, meaning no detectable disease afterward, and for many people it does not return. For indolent subtypes, the realistic aim is long-term control, with periods of remission and often long stretches needing no treatment. Both are common outcomes, and your care team can describe which applies to your diagnosis.

Is non-Hodgkin lymphoma a serious cancer?

Yes, as every cancer is, but it is also a cancer where treatment has improved substantially, particularly with monoclonal antibodies added to chemotherapy. Seriousness varies enormously by subtype: Burkitt lymphoma requires urgent intensive treatment, while a symptom-free marginal zone lymphoma may simply be monitored for years. The pathology report, not the label, tells you how serious yours is.

What is the difference between Hodgkin and non-Hodgkin lymphoma on a biopsy?

A pathologist diagnoses Hodgkin lymphoma when large abnormal B cells called Reed-Sternberg cells are present, typically surrounded by many reactive immune cells. When those cells are absent, the lymphoma is classified as non-Hodgkin and further tests identify which of the many B-cell, T-cell or NK-cell subtypes it is. Immunophenotyping, which detects surface proteins such as CD30 or CD20, confirms the distinction.

How is lymphoma treatment planned by stage?

Staging maps how many lymph node regions and organs are involved, from stage I to stage IV, with letters for B symptoms and bulky disease. In Hodgkin lymphoma, stage separates early from advanced disease and sets the number of chemotherapy cycles and radiotherapy decisions. In aggressive non-Hodgkin lymphoma, stage is combined with other factors, while in indolent lymphoma symptoms matter more than stage.

What are the main non-Hodgkin lymphoma treatment options?

Options include active monitoring for symptom-free indolent disease, chemo-immunotherapy combining chemotherapy with an anti-CD20 antibody for many B-cell types, radiotherapy for limited-stage disease, targeted oral drugs for certain subtypes, and, at relapse, stem cell transplant, CAR T-cell therapy or bispecific antibodies. Which of these is offered depends on subtype, stage, prior treatment and overall health, decided by the treating team.

Is Hodgkin lymphoma treatable at an advanced stage?

Yes. Advanced-stage classical Hodgkin lymphoma is treated with combination chemotherapy, usually more cycles than early-stage disease, with radiotherapy added in selected situations such as bulky disease. A PET-CT after the early cycles often guides whether treatment can be reduced or needs to be intensified. The intention at every stage is complete remission, and your team can discuss what the evidence shows for your situation.

Why does my doctor want to wait before treating my lymphoma?

For slow-growing non-Hodgkin lymphomas that are not causing symptoms, studies have not shown that starting treatment early helps people live longer or better, while it does add side effects. Active monitoring with regular check-ups and scans lets the team begin treatment only when the disease becomes active. It is an evidence-based plan, not an absence of one.

How long does lymphoma treatment usually take?

Chemotherapy for both Hodgkin and non-Hodgkin lymphoma is typically given in cycles over several months, according to the NHS, with rest periods between infusions and a scan partway through to assess response. Radiotherapy, when used, adds a few weeks of short daily sessions afterward. Follow-up then continues for years. Exact timelines depend on subtype, stage and response, and only your treating team can set them.

References

• Non-Hodgkin lymphoma, NHS
• Hodgkin lymphoma, NHS
• Hodgkin Lymphoma, MedlinePlus

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.